Boston Scientific Announces Schedule For Presentations At The Upcoming North American Neuromodulation Society (NANS) Meeting
Data Will Focus on Long-Term Back Pain Relief Using the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System and Highlight Research on Stimulation Waveforms

MARLBOROUGH, Mass., Nov. 3, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical programs at the 18th North American Neuromodulation Society (NANS) Meeting, being held this year in Las Vegas, December 11-14.

"We are excited about the continuing success of our next-generation Precision Spectra™ Spinal Cord Stimulator (SCS) System in providing sustained and highly significant low back pain relief, and we look forward to releasing our 'real-world' experience with 12-month clinical data," said Maulik Nanavaty, president, Neuromodulation, Boston Scientific. "In addition, we are committed to further advancing the science and understanding of pain relief with our comprehensive research program exploring both high rate therapy and novel waveforms."

Schedule of Key Presentations

Boston Scientific data will be presented during oral sessions or as posters. All programs will be held at the Mandalay Bay and Four Seasons Hotels in Las Vegas.

Precision Spectra SCS System

  • PRO Study (Low Back Pain) - One-year, multicenter consecutive case-series of patients with chronic low back pain treated with the Precision Spectra SCS System using a 32-contact multiple independent current control system (MICC).

Advanced Research Programs

  • ACCELERATE - Prospective multicenter trial evaluating high-rate (10 kHz) spinal cord stimulation in management of chronic, intractable pain.
  • WHISPER - Prospective multicenter trial evaluating the use of sub-perception MICC SCS at ≤ 1.2 kHz.
  • Preclinical Research – Preclinical model for investigating the mechanism of spinal cord stimulation.

Additionally, results will be released from the Investigator Sponsored exploratory research of the sub-perception MICC SCS at at ≤ 1.2 kHz.

For more information about the NANS 2104 Annual Meeting, please click here.

About Chronic Pain

More than 100 million Americans suffer from chronic pain.  Living in constant pain for an extended period of time can have a devastating impact on quality of life for many patients.  Without relief, or the hope for relief, many patients lose the ability to sleep, work, and function normally.  In particular, conventional spinal cord stimulator therapy can be effective in treating low back pain but not all patients get optimal relief. As a result, there is a continuing need for new therapies and technologies to meet this very specific pain area.

About the Precision Spectra SCS System

The Precision Spectra System is the world's first and only SCS system with Illumina 3D™ software and 32 contacts, which is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain.

Prior to the release of the Precision SCS Spectra System, SCS systems offered a maximum of 16 contacts and two lead ports, with each lead port allowing the placement of a single lead.  Additional lead ports give physicians more flexibility to cover their patients' pain at the time of implant and more flexibility to adapt to changing pain patterns in the future.  With more contacts, the Precision Spectra SCS System also offers more coverage of the spinal cord for the management of chronic pain.

The upgradeable Precision Spectra SCS System is designed to improve pain relief using the innovative and highly advanced Illumina 3D Software, a three dimensional anatomy-driven computer model.  A key challenge in SCS therapy is stimulating the neural target without stimulating undesired areas.  By taking into account the conductivity of 3D anatomical structures and physician placement of the SCS leads, the Illumina 3D Software is designed for simple point-and-click pain targeting.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our products, our business plans, presentations, clinical trials and impact of data, product performance and impact, and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

Media: Ryan Davenport
Global Media Relations
Boston Scientific Corporation
763-494-2664 (office)

Investors: Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
508-683-5565 (office)

SOURCE Boston Scientific Corporation